NCT05414747View on ClinicalTrials.gov

Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

NASuspendedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 15, 2023

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2025

Conditions
Retinal Detachment
Interventions
DEVICE

ABV-1701

ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)

DEVICE

SF6 Gas

SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)

Trial Locations (4)

2155

Sydney Eye Hospital, Sydney

Unknown

East Melbourne Eye Group, Melbourne

Ramathibodi Hospital, Bangkok

Srinagarind Hospital, Khon Kaen

Sponsors
All Listed Sponsors
collaborator

ABVC BioPharma, Inc

UNKNOWN

lead

BioFirst Corporation

INDUSTRY

NCT05414747 - Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE) | Biotech Hunter | Biotech Hunter